Mabwell has established an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation. The international standard drug discovery platforms and skillful & efficient development platforms enable us to develop innovative biologics efficiently and submit IND rapidly. We focus on large-scale, fast-growing therapeutic areas including oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Mabwell has 16 pipeline products. Of these, 3 products have been approved and commercialized, 1 product is undergoing market approval review, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects.
Compliant with GMP requirements in China, U.S., and EU
Integrated production capacity of monoclonal antibodies, fusion proteins, ADCs and other drug molecules to support clinical research and commercial manufacturing
Transparent factory, penetrating supervision, permeable management, flexible production
EU QP Audited
Capacity
8,000L, antibody production; 4,000L, recombinant protein production
2 drug product filling lines for pre-filling syringes & vials
Production
Undertaking production of MAILISHU & MAIWEIJIAN
Area
~53,400 ㎡
ADC production
Capable of providing drug samples for pre-clinical & early phase clinical use
Scaling up production in the kilogram can meet the needs of pivotal trials to commercialization
QA & QC (under construction)
Ready for trial production
Capacity
Designed capacity of 1,000kg per year
Digitalization
Distributed Control System greatly improves the automation of liquid preparation process
Full-automatic 3D warehouse to meet smart inventory management
The integration of automation and informatization to achieve digitalization
Market led, Medical-driven, Access first
Deeply engaged in academic promotion in autoimmune diseases, osteoporosis and oncology, we have built mature and professional marketing network in China, bringing world-class novel therapeutic options to more domestic patients. Our marketing management team is led by professionals with over 20 years of experience in average.
Improve Global Health
We are expanding to Euramerican market and emerging markets to meet the clinical needs of patients worldwide, and have entered into strategic partnerships with more than a dozen countries overseas.
License out
2023.1 - Entered into an agreement with DISC MEDICINE (NASDAQ: IRON) about 9MW3011 (R&D code in the US: MWTX-001, MWTX-002 & MWTX-003) with a total of up to $412.5 million of down payment and milestone payment.
Partnership in emerging market
Get in touch with our BD team: ib@mabwell.com
2024.11 - Established partnership with TABUK to market 2 products in MENA region
2024.11 - Established a licensing and commercialization agreement of denosumab products in Peru
2024.8 - Established a Licensing and Commercialization agreement of denosumab products with CRISTÁLIA in Brazil
2024.1 - Established a licensing and commercialization agreement to market of denosumab products in Indonesia
2023.11 - Established partnership with Innobic (wholly owned subsidiary of PTT Public Company Ltd, the state-owned enterprise and the largest company by market capitalization on Thailand Stock Exchange) to market products in Thailand
2023.10 - Established partnership with UPL to market 9MW0113 in Argentina
2023.9 - Established partnership with Legrand to market 9MW0311 & 9MW0321 in Colombia and Ecuador
2023.8 - Established partnership with UNILAB (ranks number 1 in the ASEAN pharmaceutical industry) to market 9MW0113 in the Philippines
2023.7 - Established partnership with Sothema (the biggest pharmaceutical company in Morocco) to market 9MW0113 in Morocco
2023.7 - Established partnership with Searle (one of the top pharmaceutical companies in Pakistan) to market 9MW0311 & 9MW0321 in Pakistan
2023.6 - Established a licensing and commercialization agreement of 9MW0311 & 9MW0321 for Egypt market
